Ecto-NTPDase-Inhibitors – Inhibitors for use in human therapy
The invention provides a new class of nucleosides
exhibiting a high affinity for individual ecto-nucleotidetriphosphate- diphosphohydrolases (E-NTPDases) which have been developed by researchers at the University of Bonn. The inhibitors are capable of inhibiting the metabolization of nucleotides by individual E-NTPDases and thus act as a highly selective indirect agonists of P2- receptors (ATP-, ADP-, UTP-, UDP-receptors). Therapeutic compounds which facilitate the signal transduction via P2-receptors can be used e.g. for the treatment of mucoviscidosis and cancer or for the modulation of inflammatory processes and the immune system. Furthermore, such compounds are valuable tools in biopharmaceutical research. The present invention thus comprises a novel class of therapeutically active compounds as well as methods for preparing the same.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…
